István Gyertyán
Research Division
Gedeon Richter Plc.
Budapest 1475
Hungary
Name/email consistency: high
- Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Gyertyán, I., Sághy, K., Laszy, J., Elekes, O., Kedves, R., Gémesi, L.I., Pásztor, G., Zájer-Balázs, M., Kapás, M., Agai Csongor, E., Domány, G., Kiss, B., Szombathelyi, Z. Naunyn Schmiedebergs Arch. Pharmacol. (2008)
- Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse. Gyertyán, I., Kiss, B., Gál, K., Laszlovszky, I., Horváth, A., Gémesi, L.I., Sághy, K., Pásztor, G., Zájer, M., Kapás, M., Csongor, E.A., Domány, G., Tihanyi, K., Szombathelyi, Z. J. Pharmacol. Exp. Ther. (2007)
- The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Gyertyán, I., Sághy, K. Eur. J. Pharmacol. (2007)
- Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011. Gyertyán, I., Sághy, K. Behav. Pharmacol (2004)
